“CDC and FDA are committed to expanding access to this important immunization so that more parents have peace of mind during the winter virus season,” said Dr. Nirav D. Shah, CDC’s principal deputy director.
“Helping to ensure the availability of this preventative option to reduce the impact of RSV disease on eligible babies and young children, families and the health care system remains a priority,” said Patrizia Cavazzoni, M.D, director of the FDA’s Center for Drug Evaluation and Research. “We will continue to use all our regulatory tools to help bring safe, effective and high-quality medicines to the public.”
Read the full press release from CDC and FDA.